🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Beacon Therapeutics clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA and UK registers with Beacon Therapeutics as lead sponsor. Synced 26 Sep 2026
5Current trials
0Recruiting now
1Drug in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Beacon Therapeutics is the lead sponsor of 5 current clinical trials in our USA and UK registers. None of its ClinicalTrials.gov trials is recruiting at the moment. The most common phase is Phase 2. The drugs named most often in its trials are RAAV2tYF-GRK1-RPGR. The most-studied condition is X-Linked Retinitis Pigmentosa.

ClinicalTrials.gov trials by status

  • Active, closed480%
  • By invitation120%

Trials by phase

  • Phase 2360%
  • Phase 2/3120%
  • Phase 1/2120%
01

Clinical trials sponsored by Beacon Therapeutics

5 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)
NCT06275620 · ClinicalTrials.gov ↗ · X-Linked Retinitis Pigmentosa
Phase 2 By invitation 2023-11 USA
A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP
NCT04850118 · ClinicalTrials.gov ↗ · X-Linked Retinitis Pigmentosa
Phase 2/3 Active, closed 2024-03 UK, USA
A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa
NCT07174726 · ClinicalTrials.gov ↗ · X-Linked Retinitis Pigmentosa (XLRP)
Phase 2 Active, closed 2025-09 USA
A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)
NCT06333249 · ClinicalTrials.gov ↗ · X-Linked Retinitis Pigmentosa
Phase 2 Active, closed 2021-04 USA
Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations
NCT03316560 · ClinicalTrials.gov ↗ · X-Linked Retinitis Pigmentosa
Phase 1/2 Active, closed 2018-04 USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Beacon Therapeutics trials

1 compound

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Beacon Therapeutics trials

2 conditions
X-Linked Retinitis Pigmentosa4X-Linked Retinitis Pigmentosa (XLRP)1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in USA50
Clinical trials in UK10

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in X-Linked Retinitis Pigmentosa

SponsorTrials
Frontera Therapeutics1

Sponsors with the most current trials registered for this condition.

06

Questions about Beacon Therapeutics trials

How many clinical trials does Beacon Therapeutics sponsor?

Beacon Therapeutics is the lead sponsor of 5 current trials on ClinicalTrials.gov in our USA and UK registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Beacon Therapeutics trials recruiting?

Not at the moment. None of its 5 ClinicalTrials.gov trials is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.

Which drugs is Beacon Therapeutics testing?

Its current trials name 1 drug or biological as interventions. The most frequent are RAAV2tYF-GRK1-RPGR (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.